Also found in: Medical.
SPARCLStroke Prevention by Aggressive Reduction in Cholesterol Levels
SPARCLSmart Pixel Array Cellular Logic (processor)
SPARCLSonoita Patagonia Alliance for Rural Community Learning
References in periodicals archive ?
The study subjects were ambulatory men and women with no known coronary heart disease who had had ischemic stroke, hemorrhagic stroke, or transient ischemic attack (TIA) 1-6 months before undergoing randomization in the SPARCL trial.
Amarenco P, Goldstein LB, Szarek M, Sillesen H, Rudolph AE, Callahan A 3rd, et al, SPARCL Investigators.
An analysis of the SPARCL data was conducted after the study to explore the types of strokes (ischaemic or haemorrhagic) that occurred among patients in the study.
The new SPARCL data provide physicians and patients with one more reason to
Michael Welch, SPARCL investigator, neurologist and president of Rosalind Franklin University of Medicine & Science.
The SPARCL trial (26) should provide useful information about the benefit of statin therapy in patients with TIA or stroke but no evidence of coronary or peripheral vascular disease.
The update noted that in conformity with the American Heart Association's guidelines development policy, the guidelines "assume a class effect [for all statins] in the absence of data to the contrary," although the update also noted that it is unclear whether the risk reduction seen in SPARCL was a class effect or was more specific to the regimen of 80 mg/day of atorvastatin.
An additional analysis evaluated 781 patients in the SPARCL trial who were classified as having metabolic syndrome and who had a recent stroke or mini-stroke but no known coronary heart disease.
The SPARCL study, published in the New England Journal of Medicine in 2006, is the only study to date evaluating the benefits of a statin solely in patients with a prior stroke or mini-stroke (n=4,731).
The SPARCL study is a double-blind, randomized, placebo-controlled, multicenter study that will enroll up to 4,200 patients at 140 sites worldwide.
A new SPARCL analysis was conducted to evaluate if treatment with Lipitor 80 mg was associated with significant protection from coronary events after a recurrent stroke or mini-stroke.